Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amyris, Inc.
  6. Summary
    AMRS   US03236M2008

AMYRIS, INC.

(AMRS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/01/2021 12/02/2021 12/03/2021 12/06/2021 12/07/2021 Date
6.155(c) 5.96(c) 5.7(c) 5.84(c) 6.09(c) Last
7 302 384 9 354 229 10 209 084 5 910 420 5 501 420 Volume
-10.28% -3.17% -4.36% +2.46% +4.28% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 341 M - -
Net income 2021 -370 M - -
Net Debt 2021 296 M - -
P/E ratio 2021 -4,83x
Yield 2021 -
Sales 2022 400 M - -
Net income 2022 -86,8 M - -
Net Debt 2022 94,0 M - -
P/E ratio 2022 -29,1x
Yield 2022 -
Capitalization 1 877 M 1 877 M -
EV / Sales 2021 6,37x
EV / Sales 2022 4,93x
Nbr of Employees 595
Free-Float 64,9%
More Financials
Company
Amyris, Inc. is a synthetic biotechnology company. The Company applies its Lab-to-Market biotechnology platform to engineer, manufacture and market high performance, natural and sustainably sourced products using its computational tools, strain construction tools, screening and analytics tools, and advanced lab automation and data integration. The Company's biotechnology platform enables users to rapidly engineer... 
Sector
Commodity Chemicals
Calendar
03/02Earnings Release
More about the company
Ratings of Amyris, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about AMYRIS, INC.
11/30Amyris' Black Friday Week Consumer Sales Exceed $10 Million
MT
11/30Amyris Consumer Brands Deliver Record Black Friday Week
PR
11/29AMYRIS X ART BASEL : A Conversation with Francisco Costa
PU
11/23Amyris To Present At The Evercore ISI 4th Annual HealthCONx Conference On December 1, 2..
PR
11/22Amyris, Inc. Provides Revenue Guidance for the Full Year 2021
CI
11/18ImmunityBio Expands Cancer, Infectious Disease Vaccine Programs to Use Mix-and-Match Ap..
MT
11/18Amyris To Host Call Regarding Recent Financing Activity
PR
11/15Amyris Closes Upsized Offering Of $690.0 Million Of 1.50% Convertible Senior Notes Due ..
PR
11/15AMYRIS : Purchase Agreement - Form 8-K
PU
11/15AMYRIS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial ..
AQ
11/11Amyris, Inc Mulls Acquisitions
CI
11/10Amyris Prices $600.0 Million Of 1.50% Convertible Senior Notes Due 2026
PR
11/09Health Care Stocks Slip This Afternoon as Biotechs Sputter
MT
11/09Amyris Plans $400 Million Convertible Senior Notes Offering; Shares Sink
MT
11/09Wall Street Cautiously Mixed Pre-Bell, US Producer Prices Climb 0.6% in October
MT
More news
News in other languages on AMYRIS, INC.
11/22Amyris, Inc. fournit des prévisions de revenus pour l'ensemble de l'année 2021
11/18ImmunityBio élargit ses programmes de vaccins contre le cancer et les maladies infectie..
11/09Les actions du secteur de la santé chutent cet après-midi, tandis que les biotechs vaci..
11/09Amyris propose une offre de 400 millions de dollars de billets convertibles de premier ..
11/09Aperçu des ETF. Les ETF et les contrats à terme en territoire positif alors que la Bour..
More news
Analyst Recommendations on AMYRIS, INC.
More recommendations
Chart AMYRIS, INC.
Duration : Period :
Amyris, Inc. Technical Analysis Chart | AMRS | US03236M2008 | MarketScreener
Technical analysis trends AMYRIS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 6,09 $
Average target price 20,83 $
Spread / Average Target 242%
EPS Revisions
Managers and Directors
John G. Melo President, Chief Executive Officer & Director
Hermanus Kieftenbeld Chief Financial & Administration Officer
Geoffrey Mark Duyk Chairman
Sunil Chandran Senior Vice President-Research & Development
Eduardo Alvarez Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
AMYRIS, INC.-1.38%1 877
SAUDI BASIC INDUSTRIES CORPORATION10.06%89 242
AIR LIQUIDE15.69%82 524
WANHUA CHEMICAL GROUP CO., LTD.9.29%49 063
GANFENG LITHIUM CO., LTD.50.20%32 225
ALBEMARLE CORPORATION75.93%30 359